2min chapter

Lex Fridman Podcast cover image

#279 – Alien Debate: Sara Walker and Lee Cronin

Lex Fridman Podcast

CHAPTER

Is Time Just a Word?

Time is a word, right? We kind of mentioned it a bunch. Is it not important at all in terms of, is it just a word? Should we be talking about causality mostly? Like Sarah, what do you think? We've talked about like memories. But when you get to things like us, it becomes very clear that the universe has a directionality associated to it. So it's not reversible at all. Because the no man ever steps in the same river.

00:00
Speaker 1
Buffalo, New York, July 5th, 2023. A new research paper was published in Onka Targets volume 14 on July 1st, 2023 entitled Transferation of Immunosuppressive MTK-RAS tumors into immunostimulatory tumors by Narofe and Doxarubicin. Members of the RAT sarcoma viral oncogene, RAS, subfamily, K-RAS, are frequently mutated oncogenes in human cancers and have been identified in pancreatic ductal, colorectal, and longadino carcinomas. Recently, two drugs that specifically target K-RAS G12C, serosib, or limocross, and adegrassib, or chrysati, have received accelerated approval by the FDA for the treatment of adult patients with K-RAS G12C mutated locally advanced or metastatic NSCLC, who have received at least one prior systemic therapy. These drugs are the first RAS GT-PACE family inhibitors to be approved for clinical use, representing a major breakthrough in the field of precision oncology. In this new study, researchers from immune system key ISK and Drusselen College of Technology show that a derivative of the hormone peptide tumor cell apoptosis factor, or TCAPF, Narofe, or DTCAPFS, in combination with Doxarubicin, Dox, substantially reduces viability of tumor cells. Quote, The objective of the present study was to investigate the synergistic effect of the combination of Narofe and Dox in colorectal cancer and its underlying mechanism. It was observed that the combination of Narofe and Dox downregulated K-RAS signaling via MIR217 upregulation, resulting in enhanced apoptosis of tumor cells. In addition, the combination of Narofe and Dox also resulted in activation of the immune system against tumor cells, manifested by an increase in the immunostimulatory cytokines IL-2 and IFN gamma, as well as the recruitment of NK cells and M1 macrophages to the tumor site. In conclusion, we demonstrated that the combination of Narofe and Dox exerts a synergistic effect during MCRC treatment, which could stem from several independent and complementary mechanisms of action. End quote. About OncoTarget OncoTarget, a primarily oncology-focused peer-reviewed open access journal aims to maximize research impact through insightful peer review, eliminate borders between specialities by linking different fields of oncology, cancer research and biomedical sciences, and foster application of basic and clinical science. To learn more about OncoTarget, visit oncotarget.com and connect with us on social media, we're on Twitter, Facebook, YouTube, Instagram, LinkedIn, Pinterest, LabTube, and SoundCloud. Please also visit oncotarget.com to sign up for free altmetrical ads about this article and for oncotarget publication updates. For media inquiries, please contact media at impactjournals.com.

Get the Snipd
podcast app

Unlock the knowledge in podcasts with the podcast player of the future.
App store bannerPlay store banner

AI-powered
podcast player

Listen to all your favourite podcasts with AI-powered features

Discover
highlights

Listen to the best highlights from the podcasts you love and dive into the full episode

Save any
moment

Hear something you like? Tap your headphones to save it with AI-generated key takeaways

Share
& Export

Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more

AI-powered
podcast player

Listen to all your favourite podcasts with AI-powered features

Discover
highlights

Listen to the best highlights from the podcasts you love and dive into the full episode